Narjust Florez, Co-Director of Young Lung Cancer Program at Dana-Farber Cancer Institute, shared a post on LinkedIn:
“How meaningful is “practice-changing” data if patients still cannot access the drug?
Sunvozertinib has shown promising activity in EGFR exon 20ins NSCLC, yet access remains the real endpoint that matters. A drug approval means little if, patients still cannot receive it.
Innovation is not just generating data, it is delivering therapies to the people who need them ASCO26.”
Title: First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
Authors: Caicun Zhou, Laurent Greillier, Geoffrey Liu, Thomas John, Ligang Xing, Dariusz Kowalski, Regan M. Memmott, Ozan Yazici, Meili Sun, Catherine Shu, Elvire Pons-Tostivint, Yun Fan, Gonzalo Fernandez-Hinojal, Elaine Shum, Mengzhao Wang, Federica Bertolini, D. Ross Camidge, Chengzhi Zhou, Ludovic Doucet, Qunying Hong, Jian Fang, Dingzhi Huang, Bo Jin, Yan Yu, Lorenzo Antonuzzo, Denis Moro-Sibilot, Jaafar Bennouna, Gilberto de Castro Jr., Li Zheng, John V. Heymach
Read the article here.
Other articles featuring Narjust Florez on OncoDaily.